Equities

bioAffinity Technologies Inc

BIAF:NAQ

bioAffinity Technologies Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)2.06
  • Today's Change0.05 / 2.49%
  • Shares traded155.17k
  • 1 Year change+33.77%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

bioAffinity Technologies, Inc. is a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease. The Company addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatment. Its segments include Diagnostic Research and Development (R&D) and Laboratory Services. Its Diagnostic R&D segment includes research and development and clinical development on diagnostic tests. Its Laboratory services include all the operations of Village Oaks and PPLS, in addition to sales and marketing of CyPath Lung from bioAffinity. Its first product, CyPath Lung, addresses the need for noninvasive detection of early-stage lung cancer. The CyPath Lung test enables physicians to more confidently identify patients who will likely benefit from timely intervention and more invasive follow-up procedures and those who are likely without lung cancer and should continue routine screening.

  • Revenue in USD (TTM)7.32m
  • Net income in USD-8.74m
  • Incorporated2014
  • Employees75.00
  • Location
    bioAffinity Technologies Inc22211 West Interstate-10, Suite 1206SAN ANTONIO 78257United StatesUSA
  • Phone+1 (210) 698-5334
  • Fax+1 (916) 443-1908
  • Websitehttps://bioaffinitytech.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
IR-Med Inc0.00-3.47m24.05m6.00--66.22-----0.0499-0.04990.000.00510.00----0.00-197.95---273.36--------------0.3019-------3.70------
Orgenesis Inc662.00k-29.02m25.81m146.00------38.99-0.8684-0.86840.02-0.33030.027278.295.384,534.25-122.18---1,312.10---101.06---4,489.28--0.0741-5.85-----98.53-50.94-271.82---17.71--
Femasys Inc950.09k-16.69m26.01m32.00--2.31--27.38-0.8468-0.84680.04720.50600.05490.34387.6529,690.31-96.51---108.58--65.67---1,756.83--5.93-77.250.2972---11.13---25.04------
Meihua International Medical Tech Co Ltd97.10m11.63m26.22m617.002.120.16852.170.2700.48560.48564.066.110.578846.661.31157,372.606.9112.268.1315.0534.1938.1411.9415.475.21--0.04750.00-6.055.1086.22-5.56-9.16--
Retractable Technologies Inc38.25m-18.10m26.91m148.00--0.3158--0.7035-0.6046-0.60461.282.850.22021.446.42258,468.00-10.2812.45-10.7914.5119.1940.82-46.7118.096.54-2.860.016---54.025.55-249.46--17.42--
Ekso Bionics Holdings Inc18.16m-12.42m26.99m70.00--1.91--1.49-0.7909-0.79091.130.65380.59571.653.14259,428.60-40.75-43.63-57.60-57.6751.8351.93-68.41-104.241.77-23.990.3172--41.5710.03-0.7825--3.69--
bioAffinity Technologies Inc7.32m-8.74m27.12m75.00--6.73--3.71-0.9007-0.90070.74390.29890.9422236.818.6897,545.07-112.51---140.58--35.47---119.41--1.14-296.510.234--52,660.42--2.66------
Positron Corp1.24m-1.27m27.23m22.00------22.01-0.0897-0.08970.0876-0.11090.59762.296.56---61.35-224.13----32.989.85-102.67-201.870.0638-------10.060.275163.63--4.36--
Golden Valley Development Inc0.00-92.53k27.36m0.00---------11.17-11.170.00-0.02110.00-------7,710.83-------------3,073.27---3.96--------45.48------
Neuronetics Inc72.07m-32.47m28.70m203.00--1.47--0.3983-1.10-1.102.450.64330.73092.314.76355,000.00-32.93-28.02-42.47-34.7375.9175.73-45.06-51.042.37-3.920.755--9.426.2218.76--18.57--
Neuroone Medical Technologies Corp3.96m-12.10m28.81m16.00--8.65--7.27-0.4916-0.49160.15930.10820.74281.6919.31247,702.50-226.84-172.88-334.70-274.7429.60---305.37-674.971.36--0.00--62.66---18.60------
Know Labs Inc0.00-16.34m29.68m15.00---------0.2204-0.22040.00-0.05330.00----0.00-442.53-209.16---1,087.76-------1,302.62---15.986.21---100.00---1.85---3.64--
DarioHealth Corp19.15m-46.52m30.03m223.00--0.4411--1.57-1.51-1.510.58032.270.162.393.3169,373.19-42.46-73.26-47.52-87.5930.9729.54-265.33-293.541.96--0.2961---26.4122.450.5091--52.42--
Outset Medical Inc116.43m-159.18m30.95m480.00--0.4511--0.2658-3.14-3.142.291.320.35881.583.28242,552.10-49.06-41.40-57.18-47.2928.235.71-136.72-159.055.38-18.390.7417--13.00130.43-6.04--14.27--
Data as of Sep 20 2024. Currency figures normalised to bioAffinity Technologies Inc's reporting currency: US Dollar USD

Institutional shareholders

2.85%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 2024171.99k1.28%
Geode Capital Management LLCas of 30 Jun 202469.60k0.52%
CapFinancial Partners LLCas of 30 Jun 202427.89k0.21%
Renaissance Technologies LLCas of 30 Jun 202422.97k0.17%
Ground Swell Capital LLCas of 30 Jun 202422.86k0.17%
SSgA Funds Management, Inc.as of 30 Jun 202417.60k0.13%
Sheaff Brock Investment Advisors LLCas of 30 Jun 202415.00k0.11%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 202413.66k0.10%
Creative Planning LLCas of 30 Jun 202412.60k0.09%
IFP Advisors, Inc.as of 30 Jun 202410.00k0.07%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.